DK245287A - Peptider relateret til htlv-iii virus, antistoffer mod disse peptider, vacciner til aktiv og passiv immunisering mod aids-virus og fremgangsmaade og udstyr til serologisk paavisning af aids virus - Google Patents

Peptider relateret til htlv-iii virus, antistoffer mod disse peptider, vacciner til aktiv og passiv immunisering mod aids-virus og fremgangsmaade og udstyr til serologisk paavisning af aids virus

Info

Publication number
DK245287A
DK245287A DK245287A DK245287A DK245287A DK 245287 A DK245287 A DK 245287A DK 245287 A DK245287 A DK 245287A DK 245287 A DK245287 A DK 245287A DK 245287 A DK245287 A DK 245287A
Authority
DK
Denmark
Prior art keywords
aids
viruses
htlv
iii
alpha
Prior art date
Application number
DK245287A
Other languages
English (en)
Other versions
DK173040B1 (da
DK245287D0 (da
Inventor
Allan L Goldstein
Su Sun Wang
Original Assignee
Viral Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viral Technologies Inc filed Critical Viral Technologies Inc
Publication of DK245287D0 publication Critical patent/DK245287D0/da
Publication of DK245287A publication Critical patent/DK245287A/da
Application granted granted Critical
Publication of DK173040B1 publication Critical patent/DK173040B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1143—Gag-pol proteins, e.g. p17or p24
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK198702452A 1986-05-19 1987-05-14 Peptider relateret til HIV, antigener omfattende peptiderne, antistoffermod disse peptider, vacciner og antisera til aktiv DK173040B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86459986A 1986-05-19 1986-05-19
US86459986 1986-05-19

Publications (3)

Publication Number Publication Date
DK245287D0 DK245287D0 (da) 1987-05-14
DK245287A true DK245287A (da) 1987-11-20
DK173040B1 DK173040B1 (da) 1999-11-29

Family

ID=25343634

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198702452A DK173040B1 (da) 1986-05-19 1987-05-14 Peptider relateret til HIV, antigener omfattende peptiderne, antistoffermod disse peptider, vacciner og antisera til aktiv

Country Status (17)

Country Link
EP (1) EP0246829B1 (da)
JP (3) JPH089636B2 (da)
KR (1) KR910002690B1 (da)
CN (1) CN87103568A (da)
AT (1) ATE100469T1 (da)
AU (1) AU606595B2 (da)
DE (1) DE3788822T2 (da)
DK (1) DK173040B1 (da)
ES (1) ES2061495T3 (da)
GB (1) GB2190679B (da)
IE (1) IE60274B1 (da)
IL (1) IL82471A (da)
IN (1) IN167198B (da)
MX (1) MX167236B (da)
NZ (1) NZ220200A (da)
PH (1) PH26239A (da)
ZA (1) ZA873215B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1219232A (en) * 1983-08-17 1987-03-17 Richard A. Lerner Polypeptide-induced monoclonal receptors to protein ligands
US4863730A (en) * 1986-03-21 1989-09-05 Cenfold Holdings, S.A. Immunotherapy for AIDS patients
DE346022T1 (de) * 1988-06-10 1990-05-23 Medical Research Council, London Peptidfragmente von hiv.
US5219725A (en) 1988-12-05 1993-06-15 Idexx Laboratories Incorporated Monoclonal antibodies to feline-t-lymphotropic lentivirus
DE69008712T2 (de) * 1989-02-01 1994-10-13 Du Pont Hiv p17-test für die überwachung des verlaufs von aids.
JP3058685B2 (ja) * 1989-05-08 2000-07-04 アイデックス ラボラトリーズ インコーポレーテッド ネコｔ細胞リンパトロピック レンチウィルスのポリペプチド
NZ235538A (en) * 1989-10-12 1992-06-25 Viral Technologies Inc Peptides immunoreactive with antibodies to hiv p17; carrier-bound peptides, vaccines, immunoassay and a method for forming antibody enriched sera
DE4106686A1 (de) * 1991-03-02 1992-09-03 Daimler Benz Ag Verriegelungsanordnung
FR2734281B1 (fr) * 1995-05-18 1997-07-25 Commissariat Energie Atomique Fragments d'acide nucleique derives du genome du virus vih-1, peptides correspondants et leurs applications en tant que reactifs d'evaluation du risque de transmission materno-foetale du vih-1
US6093400A (en) * 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use
CA2262432A1 (en) 1996-08-09 1998-02-19 Viral Technologies, Inc. Hiv p-17 peptide fragment, compositions containing and methods for producing and using same
US6818392B2 (en) 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof
EP1217719B1 (en) 2000-12-21 2010-11-17 Semiconductor Components Industries, LLC Method and apparatus for reducing audible noise in a power supply transformer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264571A (en) * 1979-01-22 1981-04-28 George Washington University Radioimmunoassay of thymosin α1
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
US4339427A (en) * 1980-04-14 1982-07-13 Hoffmann-La Roche Inc. Radioimmunoassay of thymosinα
US4517119A (en) * 1983-04-04 1985-05-14 Hoffmann-La Roche Inc. Synthesis of thymosin α1
US4504415A (en) * 1983-04-04 1985-03-12 Hoffman-La Roche Inc. Synthesis of thymosin α1 and desacetyl thymosin α1

Also Published As

Publication number Publication date
IL82471A (en) 1993-02-21
NZ220200A (en) 1990-08-28
GB2190679B (en) 1991-02-20
KR910002690B1 (ko) 1991-05-03
AU606595B2 (en) 1991-02-14
IE60274B1 (en) 1994-06-29
IE871289L (en) 1987-11-19
JPH0925300A (ja) 1997-01-28
EP0246829A3 (en) 1989-08-09
IN167198B (da) 1990-09-15
DE3788822T2 (de) 1994-07-28
CN87103568A (zh) 1988-01-27
DE3788822D1 (de) 1994-03-03
GB2190679A (en) 1987-11-25
JP2598245B2 (ja) 1997-04-09
ES2061495T3 (es) 1994-12-16
JPH089636B2 (ja) 1996-01-31
PH26239A (en) 1992-04-01
JPS6327498A (ja) 1988-02-05
DK173040B1 (da) 1999-11-29
ATE100469T1 (de) 1994-02-15
JPH083200A (ja) 1996-01-09
DK245287D0 (da) 1987-05-14
ZA873215B (en) 1987-10-28
KR870011154A (ko) 1987-12-21
EP0246829B1 (en) 1994-01-19
AU7313587A (en) 1987-11-26
MX167236B (es) 1993-03-11
EP0246829A2 (en) 1987-11-25
IL82471A0 (en) 1987-11-30
GB8711567D0 (en) 1987-06-17

Similar Documents

Publication Publication Date Title
Schable et al. Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections
Nara et al. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses
Rusche et al. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
Albert et al. A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB
Robey et al. Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody.
Matthews et al. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.
CA1280363C (en) Peptide composition and method for the detection of antibodies to htlv-iii
Looney et al. Type-restricted neutralization of molecular clones of human immunodeficiency virus
DK245287D0 (da) Peptider relateret til htlv-iii virus, antistoffer mod disse peptider, vacciner til aktiv og passiv immunisering mod aids-virus og fremgangsmaade og udstyr til serologisk paavisning af aids virus
Nara et al. Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies
MY104208A (en) Non-a, non-b hepatitis virus antigen peptide.
PT90376B (pt) Processo para a preparacao de peptidos env-codificados de hiv capazes de elicitarem anticorpos que inibem hiv em mamiferos e de anticorpos monoclonais que inibem hiv mediante utilizacao desses peptidos
DE68928130D1 (de) Synthetische vom HIV-GP120-env-Protein abgeleitete Peptide und ihre Anwendung
RU96116005A (ru) Штамм hominis immunodeficiti virus (hiv-i) вич-i/россия/гм-12-95 (ru1295) субтипа в для диагностических и вакцинных препаратов
Haynes et al. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
Kovacs et al. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
FI101797B (fi) STLV-III-virukseen liittyvät polypeptidit, diagnostiset järjestelmät j a määritysmenetelmät
EA200300335A1 (ru) Регуляторные и вспомогательные пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
Fischinger et al. Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I,-II,-III)
McPhee et al. Recognition of envelope and tat protein synthetic peptide analogs by HIV positive sera or plasma
Böttiger et al. Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135)
US6093400A (en) Modified HGP-30 peptides, conjugates, compositions and methods of use
PT90329B (pt) Processo para a preparacao de peptidos protectores derivados do virus-1 da imunodeficiencia humana, gp 160
Zandomeni et al. The trans-activating C-type retroviruses share a distinct epitope (s) that induces antibodies in certain infected hosts
Benjouad et al. Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed